Literature DB >> 7933088

Improved self-inactivating retroviral vectors derived from spleen necrosis virus.

P Olson1, S Nelson, R Dornburg.   

Abstract

Self-inactivating (SIN) retroviral vectors contain a deletion spanning most of the right long terminal repeat's (LTR's) U3 region. Reverse transcription copies this deletion to both LTRs. As a result, there is no transcription from the 5' LTR, preventing further replication. Many previously developed SIN vectors, however, had reduced titers or were genetically unstable. Earlier, we reported that certain SIN vectors derived from spleen necrosis virus (SNV) experienced reconstitution of the U3-deleted LTR at high frequencies. This reconstitution occurred on the DNA level and appeared to be dependent on defined vector sequences. To study this phenomenon in more detail, we developed an almost completely U3-free retroviral vector. The promoter and enhancer of the left LTR were replaced with those of the cytomegalovirus immediate-early genes. This promoter swap did not impair the level of transcription or alter its start site. Our data indicate that SNV contains a strong initiator which resembles that of human immunodeficiency virus. We show that the vectors replicate with efficiencies similar to those of vectors possessing two wild-type LTRs. U3-deleted vectors carrying the hygromycin B phosphotransferase gene did not observably undergo LTR reconstitution, even when replicated in helper cells containing SNV-LTR sequences. However, vectors carrying the neomycin resistance gene did undergo LTR reconstitution with the use of homologous helper cell LTR sequences as template. This supports our earlier finding that sequences within the neomycin resistance gene can trigger recombination.

Entities:  

Mesh:

Year:  1994        PMID: 7933088      PMCID: PMC237143     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

Review 2.  Gene therapy for genetic diseases.

Authors:  D B Kohn; W F Anderson; R M Blaese
Journal:  Cancer Invest       Date:  1989       Impact factor: 2.176

3.  New procedure for DNA transfection with polycation and dimethyl sulfoxide.

Authors:  S Kawai; M Nishizawa
Journal:  Mol Cell Biol       Date:  1984-06       Impact factor: 4.272

4.  Multiple arrangements of viral DNA and an activated host oncogene in bursal lymphomas.

Authors:  G S Payne; J M Bishop; H E Varmus
Journal:  Nature       Date:  1982-01-21       Impact factor: 49.962

Review 5.  Cellular oncogenes and retroviruses.

Authors:  J M Bishop
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

6.  Proviral deletions and oncogene base-substitutions in insertionally mutagenized c-myc alleles may contribute to the progression of avian bursal tumors.

Authors:  D Westaway; G Payne; H E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

7.  High-efficiency gene transfer into mammalian cells: generation of helper-free recombinant retrovirus with broad mammalian host range.

Authors:  R D Cone; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

8.  Nucleic acid sequences of the oncogene v-rel in reticuloendotheliosis virus strain T and its cellular homolog, the proto-oncogene c-rel.

Authors:  K C Wilhelmsen; K Eggleton; H M Temin
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

9.  Plasmid-encoded hygromycin B resistance: the sequence of hygromycin B phosphotransferase gene and its expression in Escherichia coli and Saccharomyces cerevisiae.

Authors:  L Gritz; J Davies
Journal:  Gene       Date:  1983-11       Impact factor: 3.688

10.  Construction of a helper cell line for avian reticuloendotheliosis virus cloning vectors.

Authors:  S Watanabe; H M Temin
Journal:  Mol Cell Biol       Date:  1983-12       Impact factor: 4.272

View more
  8 in total

1.  Psi- vectors: murine leukemia virus-based self-inactivating and self-activating retroviral vectors.

Authors:  K A Delviks; W S Hu; V K Pathak
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Evaluation of residual promoter activity in γ-retroviral self-inactivating (SIN) vectors.

Authors:  Wenqin Xu; Jill L Russ; Maribeth V Eiden
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

3.  A conditional self-inactivating retrovirus vector that uses a tetracycline-responsive expression system.

Authors:  J J Hwang; L Li; W F Anderson
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

4.  The U3 region of Moloney murine leukemia virus contains position-independent cis-acting sequences involved in the nuclear export of full-length viral transcripts.

Authors:  Natalia A Volkova; Elena G Fomina; Viktoryia V Smolnikova; Natalia A Zinovieva; Igor K Fomin
Journal:  J Biol Chem       Date:  2014-05-30       Impact factor: 5.157

5.  E- vectors: development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy.

Authors:  J G Julias; D Hash; V K Pathak
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Mapping of receptor binding domains in the envelope protein of spleen necrosis virus.

Authors:  I Martinez; R Dornburg
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

7.  Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery.

Authors:  R Zufferey; T Dull; R J Mandel; A Bukovsky; D Quiroz; L Naldini; D Trono
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

8.  The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery.

Authors:  Donald S Anson
Journal:  Genet Vaccines Ther       Date:  2004-08-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.